Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C.

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Abstract Text:

Hidetsugu Saito,Shinichiro Tada,Hirotoshi Ebinuma,Hiromasa Ishii,Kazuo Kashiwazaki,Jiro Nishida,Takeshi Yoshida,Shigeyuki Zeki,Hideo Yoshida,Masahiro Yoshioka,Yasutaka Inagaki,Naoki Kumagai,Toshifumi Hibi,

We examined therapeutic superiority of induction therapy with twice-daily IFN-beta (3X2=6 million units/day) onto 6-months consensus interferon monotherapy for chronic hepatitis C. Patients were randomly assigned to monotherapy without (group I, n=16) and with induction therapy (group II, n=12). The mean age of group II was older than that of group I, and other baseline condition was not statistically significant. Sustained virological response (SVR) rates of group I and II were 81.3% (13/16) and 58.3% (7/12), respectively (p=0.365). SVR rates in patients with genotype 1b were 66.7% (4/6) and 0% (0/2, because of drop-out), and those with high viral load were 70% (7/10) and 75% (6/8) in group I and II, respectively (p=1.000). Drop-out rates during therapy were 6.3% (1/16) and 33.3% (4/12) in group I and II, respectively (p=0.176). Age less than 50 years was the only independent factor that was shown by multivariate logistic model analysis to be associated with a sustained virological response. Although randomization failed to produce and equal age distribution in the two groups in this study, our results suggest that induction therapy with twice-daily IFN-beta has no beneficial effect on the efficacy of monotherapy with consensus interferon, probably because of the higher drop-out rates and incidence of adverse reactions with induction therapy.

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Publishing Authors By Initials

H Saito,S Tada,H Ebinuma,H Ishii,K Kashiwazaki,J Nishida,T Yoshida,S Zeki,H Yoshida,M Yoshioka,Y Inagaki,N Kumagai,T Hibi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: The Keio journal of medicine

VOLUME: 55

Page Numbers: 111-7

Journal Abbreviation:

ISSN: 0022-9717

DAY: 29

MONTH: Sep

YEAR: 2006

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376354

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C.

AFFILIATION: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan. hsaito@sc.itc.keio.ac.jp

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Keio J Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C Related Publications

• A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.
• A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis.
• Analysis of linear growth during puberty.
• Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention.
• Butter feeding enhances TNF-alpha production from macrophages and lymphocyte adherence in murine small intestinal microvessels.
• CXCL12 and CCL20 play a significant role in mucosal T-lymphocyte adherence to intestinal microvessels in mice.
• Clinical usefulness of urinary growth hormone measurement in short children.
• Contribution of Irf-1 promoter polymorphisms to the Th1-type cell response and interferon-beta monotherapy for chronic hepatitis C.
• Could frameshift mutations in the frxA and rdxA genes of Helicobacter pylori be a marker for metronidazole resistance?
• Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach.
• Education and imaging. Gastrointestinal: enhanced gastric mucosal blood flow in aspirin intoxication.
• Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis.
• Enhanced ghrelin expression and subsequent acid secretion in mice with genetic H(2)-receptor knockout.
• Enhanced plasma ghrelin levels in patients with functional dyspepsia.
• Evaluation of alcohol metabolism in humans using the non-invasive [C]-ethanol breath test - influence of gender, Helicobacter pylori infection and polymorphism of alcohol-oxidizing enzymes.
• Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration.
• Increased levels of plasma ghrelin in peptic ulcer disease.
• Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C.
• Intravenous ghrelin administration enhances gastric acid secretion - evaluation using wireless pH capsule.
• Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells.
• Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study.
• Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
• Reduced Shh expression in TFF2-overexpressing lesions of the gastric fundus under hypochlorhydric conditions.
• Reduced conscious blood flow in the stomach during non-steroidal anti-inflammatory drugs administration assessed by flash echo imaging.
• Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
• [Changes of parameters in long-term survivors after mitral commissurotomy (author's transl)]
• [Detection of Björk-Shiley prosthetic valve malfunction using intraoperative epicardial echocardiography]
• [Ghrelin - a novel appetite-stimulating hormone which also affects gastrointestinal functions]
• [Intraoperative epicardial two-dimensional and pulsed Doppler echocardiography for assessing functional tricuspid regurgitation]
• [Present status and future of real-time two-dimensional Doppler echocardiography]